Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors

Table 1 Correlations between clinicopathological features and CC chemokine receptor type 8 expression in gastrointestinal stromal tumors

Characteristic	n	CCR8-, n (%)	CCR8+, n (%)	Pearson χ2	P value
Total	125	51 (40.80 )	74 (59.20)
Gender				1.439	0.230
Male	62	22 (35.48)	40 (64.52)
Female	63	29 (46.03)	34 (53.97)
Age				2.268	0.132
≤ 60 yr	81	37 (45.68)	44 (54.32)
> 60 yr	44	14 (31.82)	30 (68.18)
Tumor size, cm				8.999	0.01
< 5	25	16 (64.00)	9 (36.00)
5-10	80	30 (37.50)	50 (62.50)
> 10	20	5 (25.00)	15 (75.00)
Mitotic index, per 50 HPFs				8.196	0.017
0-5	70	34 (48.57)	36 (51.43)
6-10	30	13 (43.33)	17 (56.67)
> 10	25	4 (16.00)	21 (84.00)
Gross classification				1.035	0.309
Single nodule	92	40 (43.48)	52 (56.52)
Multiple nodules	33	11 (33.33)	22 (66.67)
Tumor location				11.673	0.003
Stomach	69	34 (49.28)	35 (50.72)
Intestine	42	9 (21.42)	33 (78.58)
Others	14	9 (64.29)	5 (35.71)
AFIP-Miettinen risk classification				4.308	0.038
Very low–Moderate risk	85	40 (47.06)	45 (52.94)
High risk	40	11 (27.50)	29 (72.50)

P < 0.05. CCR8: A proliferation-inducing ligand; GIST: Gastrointestinal stromal tumors; HPFs: High-power fields.